Status:

UNKNOWN

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Lead Sponsor:

Eye & ENT Hospital of Fudan University

Conditions:

Oropharynx Carcinoma

Eligibility:

All Genders

18-90 years

Brief Summary

This is a prospective, observational study evaluating the effect and efficiency of different clinical treatments for patients with oropharyngeal carcinoma (OPC). The selection of treatment for individ...

Detailed Description

For early-stage oropharyngeal carcinoma (T1-2,N0), radiotherapy or resection of the primary tumor (transoral laser microsurgery, transoral robotic surgery, conventional transoral surgery, and open sur...

Eligibility Criteria

Inclusion

  • Oropharyngeal cancer: Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate;
  • T1, T2, T3, and T4 stage.
  • Age 18 - 90.
  • Male or female.
  • Good compliance.
  • No other severe related diseases that may impact the treatment (such as other tumors, severe heart, lung and central nervous system diseases, etc.).
  • Negative pregnancy test (for female patients with fertility).
  • Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients do not have fertility. Female patients with postmenopausal status.

Exclusion

  • Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases.
  • Patients with a known history of active tuberculosis (TB).
  • Pregnant women or lactating women.
  • The doctors believes that it is inappropriate for patients to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \[within the past year\] or active suicidal ideation or behavior).

Key Trial Info

Start Date :

April 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2025

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT05341479

Start Date

April 1 2022

End Date

July 1 2025

Last Update

April 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Otorhinolaryngology, Eye & ENT Hospital

Shanghai, Shanghai Municipality, China, 200031